Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=C7280102
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Effet bénéfique de l?association hydroxychloroquine/azithromycine dans le
traitement des patients âgés atteints de la COVID-19 : résultats d?une étude
observationnelle
#MMPMIDC7280102
Pirnay G
; Dantier B
; Tourid W
; Terkemani A
; Bachot F
; Hadim L
; Abdous N
; Amara W
; Abrous Z
; Bozel A
; Gaubert-Dahan ML
; Aikpa R
; Fauvelle F
?-/-? 2020[Dec]; 55
(4
): 398-403
PMIDC7280102
show ga
Sixty-eight patients, all over 65 years of age and diagnosed PCR-positive for
COVID-19, received the hydroxychloroquine/azithromycin combination between March
27 and May 1, 2020. Dosages of hydroxychloroquine and azithromycin were in
accordance with the protocol of the ?Institut hospitalo-universitaire de
Marseille?. The mean age was 86.4 ± 8.2 years, mean BMI was 22.8 ± 5.2 kg/m(2).
Nineteen patients were overweight (BMI greater than 25 kg/m(2)), four of whom
were obese (BMI greater than 30 kg/m(2)). Seven patients had renal impairment of
less than 30 mL/min. The survey of associated conditions indicated that about
51.5% of patients had high blood pressure while 28% had heart disease. Of these,
16.2% had diabetes. Only one patient had asthma and one had COPD. Two patients
had to stop their treatment after 3 and 9 days of dual therapy respectively due
to QTc prolongation. The objective of our study was to evaluate the efficacy of
the hydroxychloroquine/azithromycin combination in elderly subjects with
COVID-19. During the study period, 7 of the 68 patients studied died. All deaths
occurred due to severe respiratory complications of the disease. The remaining
patients were considered cured after clinical signs disappeared 21 days after the
PCR+ test.
free
free
free
